New imaging agent could help match pancreatic cancer patients to the right therapy
NCT ID NCT03851237
First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This early-phase study tested a new PET imaging agent (64Cu-DOTA-ECL1i) in 69 people with pancreatic cancer to see if it can detect a specific marker (CCR2) on tumors. The goal was to find out whether the scan can predict how well a patient will respond to standard chemotherapy or a targeted therapy. If successful, this approach could help doctors choose the most effective treatment for each patient and avoid unnecessary side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.